Viatris reports FY2022 revenue $16.3B, meets adjusted guidance; provides 2023 outlook

Viatris Inc

2022-FY EPS reported $1.71 revenue$16,262,700,000

FY2022 total revenues $16,263M; adjusted EBITDA $5,777M; free cash flow $2,547M.
2023 guidance midpoint implies revenue growth over 2022 excluding full-year biosimilars impact; reaffirms 2024 Phase 2 outlook.
Board approves 2023 dividend policy of $0.48 per share annually; Q1 dividend $0.12 per share declared.
Completed $250M in share repurchases; paid down ~$3.3B debt in 2022, $5.4B since 2021.
On track to execute planned divestitures; biosimilars transaction closed in Q4 2022.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viatris Inc updated its 2023 guidance (initiated).

Period: 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viatris Inc reported the period ended December 31, 2022 results: revenue $16,263.

Period: the period ended December 31, 2022
Revenue: $16,263
Result: reported results

Exact text from the filing

Total Revenues $16,200 - $16,700 $(86) $— $16,100 - $16,600 $16,263

View on SEC.gov

Browse all earnings releases →

Viatris Inc filing history →

Source: SEC EDGAR

accession 0001792044-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.